

ENRICO MINI
CURRICULUM VITAE

PERSONAL DATA

Date of Birth: February 22, 1952

Place of Birth: Livorno, Italy

ADDRESS

Section of Clinical Pharmacology and Oncology

Department of Health Sciences (UniFI)

Florence University

Phone: 055-2758221

e-mail: enrico.mini@unifi.it

ORCID: 0000-0003-1853-8557

EDUCATION

1988: PhD in Pharmacology and Toxicology, UniFI

1980: Specialty in Oncology, University of Modena

1977: MD, with honors, UniFI

CURRENT POSITIONS

Academic:

2008- Professor of Medical Oncology, UniFI

1992- Head, Laboratory of Cancer Pharmacology and Chemotherapy, UniFI

Clinical:

2014- Director, Unit of Translational Oncology, Careggi University Hospital (AOUC), Florence

PREVIOUS POSITIONS

Academic:

2011-2020 Director, Specialty School of Medical Oncology, UniFI

2001-2008: Professor of Pharmacology, Department of Pharmacology, UniFI

1992-2001: Associate Professor of Pharmacology, Department of Pharmacology, UniFI

1988-1992: Lecturer (Cancer Pharmacology), University of Ferrara

1983-1987: Lecturer (Cellular Pharmacology), University of Siena

1981-1984: Research Scientist, Depts Pharmacology and Internal Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, CT, USA

Clinical:

2004-2014: Program Director/Attending Physician, Unit of Oncological Pharmacology, AOUC, Florence

1993-2004: Attending Physician, Service of Clinical Pharmacology, Unit of Chemotherapy, AOUC, Florence

VISITING APPOINTMENTS

July-September 2010: Visiting Professor, Dept. Pharmacology, Yale University School of Medicine, New Haven CT, USA

May-July 1989, September 1990: Visiting Scientist, Cornell University Graduate School of Medical Sciences, Laboratory of Molecular Pharmacology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

May 1987, September-October 1987: Visiting Scientist, Departments of Internal Medicine (Section of Medical Oncology) and Pharmacology, Yale University School of Medicine, New Haven CT, USA

HONORS AND AWARDS

1989: UniFI, Italy - Viviana Minozzi Bartolozzi Award
1988-1990: Lady Tata Memorial Trust (LTMT), London, UK - LTMT Award
1988: Italian Society of Pharmacology (SIF), Milan, Italy - Alberico Benedicenti Special Mention Award
1988: National Research Council (CNR), Rome, Italy/National Institute of Health (USA) - Fellowship abroad
1985: International Union against Cancer (UICC), Geneva, Switzerland - International Cancer Research
Technology Transfer (ICRETT) Award
1982-1984: Leukemia Society of America (LSA), New York, NY, USA - Special Fellowship
1981, 1985, 1986: National Research Council (CNR), Rome, Italy - Fellowship abroad
1980-1981: Italian Association for Cancer Research (AIRC), Milan, Italy - Fellowship abroad

MEMBERSHIP OF COMMITTEES/BOARDS/RESEARCH-STUDY GROUPS

2022-: Supervising Monitor of Instand-NGS4P for the Precommercial Procurement Project Evaluated Committee (PCPEC) for NGS in Healthcare Consortium, Diagnostic and Research Institute of Pathology, Medical University of Graz - MED CAMPUS Graz, Austria
2021 -: Member of Instand-NGS4P for the Precommercial Procurement Project (PCP) for NGS in Healthcare Consortium, Diagnostic and Research Institute of Pathology, Medical University of Graz - MED CAMPUS Graz, Austria
2019-2020: Member of the Scientific Committee, Onconest Joint Research Unit (JRU), University of Tor Vergata, Rome, ULSS 3 Serenissima, Venice, Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone". Palermo, University of Florence, Florence, Istituto per lo Studio la Prevenzione e la Rete Oncologica (ISPRO), Florence, Italy
2015-: UniFI Delegate for Oncology Research, Dipartimento Interaziendale di Area Vasta Centro (D.I.A.V.C.) per la Prevenzione, Diagnosi e Cura delle Malattie Oncologiche, Regione Toscana
2015-: Member, Unit of Translational Hematology and Oncology, Center of Excellence for the Study at Molecular Level of Chronic, Degenerative and Neoplastic Diseases to Develop Novel Therapies (DENOTHE), UniFI
2015-: Member, European Organization for Research and Treatment of Cancer (EORTC) – Lung Cancer Group
2015-: Member, Department Committee, Department (DAI) of Oncology - AOUC
2013-: Member and Secretary, Executive Committee, Italian Society of Chemotherapy (SIC)
2012-: Member, Interdepartmental Center 'Development of Mini-Invasive New Technologies in Oncological Surgery' (COMIS)
2012-2013: Member, Interdepartmental Center 'Research on Pharmacoutilization, Pharmacoepidemiology, Pharmacovigilance and Pharmacoeconomy' (CIRF)
2012-: Member, Working Group on Oncological Pharmacology, Italian Society of Pharmacology (SIF)
2007-2011: Member and Secretary, Executive Committee, SIC
2007-2013: Chairman, Cancer Section, International Society of Chemotherapy (ISC) (London)
2007-2013: Member, Executive Committee, ISC (London)
2005-2007: Member, Executive Committee, SIC
2005-2007: Secretary, Cancer Section, ISC (London)
2004-2012: Member of the Technical-Scientific Committee of Tuscan Cancer Institute, Tuscany Region

1998-: Member, Steering Committee, EORTC, PAN-European Trials in Adjuvant Colon Cancer (PETACC) (Bruxelles)

1998-: Member, EORTC – Gastrointestinal Cancer Group

1997-2001: Member, Executive Committee of the Italian Society of Chemotherapy

1997-2001: Member, Executive Committee, Italian Society of Immunopharmacology

1993-2006: Expert for Antitumor Chemotherapy for the Ethics Committee for Clinical Drug Trials - AOUC

1991-: Secretary, Italian Oncological and Surgical Cooperative Group (GOCCI), Florence

1991-1994: Secretary, Technical-Scientific Committee - Italian Antineoplastic Carriers Consortium (CIVA), Italian National Program on Drugs (Rome)

1987-: Member, EORTC – Pharmacology and Molecular Mechanisms (PAMM) Group

PROFESSIONAL SOCIETIES

American Society for Microbiology (ASM)

European Society of Medical Oncology (ESMO)

European Association for Cancer Research (EACR)

Associazione Italiana di Immunofarmacologia

Società Italiana di Farmacologia (SIF)

European Organisation for Research and Treatment of Cancer (EORTC)

EORTC-Pharmacology and Molecular Mechanisms (PAMM) Group

American Society of Clinical Oncology (ASCO)

American Association for Cancer Research AACR)

Italian Association of Medical Oncology (AIOM)

Italian Society of Chemotherapy (SIC)

MEMBERSHIPS OF EDITORIAL BOARDS

2022: Guest Editor, Special issue 'Advanced Research of Drug Resistance in Gastrointestinal (GI) Cancers', Cancer Drug Resistance

2022 :Guest Editor, Special issue 'Genetics, Genomics, and Precision Medicine in Colorectal Cancer', Journal of Personalized Medicine

2021-: Editor in Chief, Section of 'Pharmacogenetics', Journal of Personalized Medicine

2020: Guest Editor, Special issue 'Gastrointestinal Cancers and Personalized Medicine', Journal of Personalized Medicine

2020-2021: Associate Editor, section of 'Oncology & Cancer Biology', Exploration of Medicine

2020-: Co-Editors-in-Chief, Cancer Cells and Therapy

2019: Co-Editor, Special issue 'Pharmacogenetics of Cancer', Cancer Drug Resistance,

2018-: Editorial Board Member, Journal of Personalized Medicine

2018: Guest Editor, Special Issue "Biomarkers in Colorectal Cancer", Journal of Personalized Medicine

2018 -: Co-Editors-in-Chief, European Continent, Oncology Research

2017-: Editorial Board Member, Cancer Drug Resistance

2015-: Associate Editor, Frontiers in Oncology

2015-: Associate Editor, Frontiers in Pharmacology

2015: Host Editor, Issue 'Multidrug resistance in cancer: molecular basis, pharmacological strategies and clinical issues', Frontiers in Oncology

2015 -2017: Editorial Board Member, Oncology Research

2014 -: Editorial Board Member, World Cancer Research Journal

2014 -2018: Editorial Board Member, European Journal of Oncology

2014 -2016: Editorial Board Member, Cell Death in Therapy

2006 -2011: Associate Editor, Metal-Based Drugs

2002 -: Editor, Journal of Chemotherapy

1997 – 2002: Field Editor - Anticancer Chemotherapy, Journal of Chemotherapy

REVIEWER ACTIVITY

Cancer pharmacology and medical oncology for several peer reviewed key scientific journals and primary national and international granting societies/institutions (e.g., Worldwide Cancer Research UK, London, UK; Swiss Cancer League, Bern, Switzerland; Dutch Cancer Society, Amsterdam, The Netherlands; Children Cancerfree (KiKa) Foundation, Amstelveen, The Netherlands; Dartmouth Medical School, Hanover, NH, USA; University of Sharjah, Sharjah, United Arab Emirates; Qatar National Research Fund, Doha, Qatar; Ministero dell'Istruzione dell'Università e della Ricerca, MIUR, Roma, Italia)

RESEARCH GRANTS AWARDED

Prof. Mini's preclinical and translational research programs are currently supported by Horizon 2020 - European Commission, Ricerca Salute Regione Toscana, Ente Cassa di Risparmio di Firenze, Intesa San Paolo, Associazione Giacomo Onlus, Gruppo Oncologico Chirurgico Cooperativo Italiano and other private and public research fundings. His research programs have been previously funded by the above and several other institutions (e.g., Associazione Italiana per la Ricerca sul Cancro (AIRC), Istituto Toscano Tumori (ITT), Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR), Ministero della Salute, Consiglio Nazionale delle Ricerche, Regione Toscana, NATO, Fédération Francophone de Cancérologie Digestive).

In particular, Prof. Mini acted as Principal Investigator/Scientific Coordinator in 3 *Progetti di Rilevante Interesse Nazionale* (PRIN) (n. 2003053403/2003; n. 2005065797/2005; n. 20084TASKL/2008) and as Associated Investigator in 2 PRIN (n. 9806301873_004/1998; n. 9906278347_005/1999) of MIUR. All of them concerned molecular mechanisms of drug resistance in gastrointestinal neoplasms (mainly colorectal cancer), novel pharmacological strategies to revert this phenomenon and identification of potentially predictive biomarkers of drug resistance.

CLINICAL RESEARCH:

Prof. Mini has participated to several national and international clinical trials as a PI or Co-I.

Prof. Mini has experience in clinical trials under ICN-GCP as certified by Syneos Health (Training Certificate no. 498654).

TEACHING ACTIVITY

Currently Prof. Mini holds Medical Oncology courses at the School of Sciences of Human Health (Medicine and Surgery and others 3 healthcare Degree Programs at this School) and at the School of Phycology; an Oncology Diagnostics course at the Biotechnologies Degree Program; Oncology courses at various Medical Specialty Schools and Masters, UniFI.

Previously he held Pharmacology courses at Medicine and Surgery and Biotechnologies Degree Programs, at various Medical Specialty Schools (UniFI).

From 2011 he is member of the Council of the Doctorate School in Pharmacology, Toxicology and Innovative Therapies (UniFI).

From 1995 to 2011 he was a member of the Council of the Doctorate School in Molecular and Cellular Physiology, Pharmacology, and Toxicology (University of Siena).

TUTORSHIPS

Prof. Mini has supervised at UniFI, Pharmacology and Toxicology Ph.D. student thesis, M.D., B.S., Pharm. And Biotechnology student thesis, Pharmacology and Medical Oncology Specialty School student thesis work.

MAJOR RESEARCH INTERESTS

Molecular mechanisms of tumor drug resistance and pharmacological strategies to overcome this phenomenon. Pharmacology of antimetabolites and metal-based drugs. Cancer pharmacogenomics and pharmacogenetics. Medical treatment of colorectal cancer. Clinical trials in medical oncology.

INVITED TALKS

Prof. Mini has been invited to give approximately 200 lectures including keynote lectures at national and international congresses or seminars at universities in Italy and abroad.

PUBLICATIONS

Author of more than 200 peer reviewed original articles and more than 50 reviews, editorials, letters (<https://www.ncbi.nlm.nih.gov/pubmed?term=Mini+E%5Bauthor%5D&cmd=detailssearch>) and book chapters. He has also shared results of his research through approximately 400 communications at national and international meetings.

SCIENTIFIC INFORMATION IN REPOSITORIES

Garziera M, Cecchin E, Lonardi S, Mini E, Nobili S, Romanato L., Toffoli, G. A novel germline mutation +3037 C>A and presence of rare variants in the HLA-G 3' UTR region in a cohort of 308 colorectal cancer patients in Italy. KP090034, NCBI GenBank (<http://www.ncbi.nlm.nih.gov/nuccore/KP090034>) - Homo sapiens MHC class I antigen (HLA-G gene, 3' UTR

ORGANIZATIONAL ACTIVITIES

Prof. Mini has organized several national and international congresses, conferences, symposia.

KEY BIBLIOMETRIC NUMBERS

From Journal Citation Reports (ISI)

Cumulative Impact Factor: 1912.198

Mean Impact Factor: 9.106

From Google Scholar MyCitations

Results found: 375

Sum of the Times Cited: 14392

Average Citations per Item: 38.37

h-index: 58

h-10-index: 161

From Scopus

Results found: 250

Sum of the Times Cited: 10037

Average Citations per Item: 40.14

h-index: 51

Florence, July 2022